BSE Sensex S&P CNX 19,990 6,069 Bloomberg JOL IN Equity Shares (m) 159.3 M.Cap. (INR b)/(usd b) 26.0/0.5 52-Week Range (INR) 248/154 1,6,12 Rel. Perf. (%) -18/-28/-34 Financials & Valuation (INR b) Y/E March 2013 2014E 2015E Sales 51.4 59.0 68.5 EBITDA 10.2 11.9 14.0 Net Profit 2.2 4.9 5.7 Adj. EPS (INR) 8.3 31.0 35.7 EPS Gr. (%) -38.9 272.6 14.9 BV/Sh. (INR) 156.6 183.0 213.3 RoE (%) 5.5 18.3 18.0 RoCE (%) 10.6 16.1 17.0 Payout (%) 15.0 15.0 15.0 Valuations P/E (x) 19.6 5.2 4.6 P/BV (x) 1.4 1.2 1.0 EV/EBITDA (x) 5.5 4.7 3.9 Div. Yield (%) 0.7 2.4 2.8 9 May 2013 4QFY13 Results Update Sector: Healthcare CMP: INR163 TP: INR213 Neutral Jubilant Life Sciences 4QFY13 results were in line with estimates. Key highlights: Jubilant Life Sciences (JOL) 4QFY13 operational performance was in line with estimates. Sales were up 18.5% YoY to INR13.88b (v/s est INR13.3b), EBITDA was up 29% YoY to INR2.33b (v/s est INR2.25b), while EBITDA margin stood at 16.8% (v/s est of 17%). JOL reported a net loss of INR310m v/s a net loss of INR635m last year. PAT, adjusted for exceptional items, fell 5% to INR454m (v/s est INR915m), mainly impacted by higher tax outgo and forex losses. Top line growth was led by a 24% growth in Life Sciences business to INR6.9b, while Pharma business grew 13% to INR7b. Growth due to favorable forex was 7%. EBITDA margin expanded by 130bp YoY (in-line), aided by increased capacity utilization in Life Sciences division and better product mix in Pharma business. Guidance: While management refrained from giving specific guidance for FY14, it retained long term guidance of 20% revenue CAGR over FY13-15E, with EBITDA margin at 21% in FY15. Tax rate has been guided at 30% over the next two years, with a capex guidance of INR3.5b. Valuation and view: Post 4QFY13 results, we lower FY14E/15E EPS estimates by 5%/6%, mainly due to the high tax guidance at 30%, against our earlier guidance of 25%. For the FY13-15E period, we expect JOL to record 15.5% top line CAGR, 17% EBITDA CAGR and 60% EPS CAGR (on a low base). EPS CAGR will be much higher than EBITDA CAGR due to large forex losses in FY13. High debt (net debt was INR34.32b as in Mar-13) continues to be our main concern. We believe JOL needs to restructure its balance sheet significantly for the stock to get re-rated. We also believe that some of its past acquisitions (like Draxis) have been made at expensive valuations, resulting in extended payback periods and lower return ratios. The stock trades at 5.2x FY14E EPS and 4.6x FY15E EPS. We maintain Neutral with a target price of INR213 (6x FY15E EPS). Hardick Bora (Hardick.Bora@MotilalOswal.com); +91 22 39825423 Investors are advised to refer through disclosures made at the end of the Research Report.
Operational performance was in line with estimates Sales were up 18.5% YoY to INR13.88b (v/s est. INR13.3b), EBITDA was up 29% YoY to INR2.33b (v/s est INR2.25b) while EBITDA margins stood at 16.8% (v/s est of 17%). Topline growth was led by a 24% growth in Life Sciences business to INR6.9b, while the Pharma business grew 13% growth to INR7b. Growth due to favorable foreign currency was 7%. The company reported net loss of INR310m against net loss of INR635m last year. PAT Adjusted for exceptional items de-grew 5% to INR454m (v/s est INR915m) mainly impacted by higher tax outgo and forex losses. Adjusted EBITDA growth of 29% - Impacted by lower margins in LSI business While the company has reported a 13% YoY EBITDA growth, 4QFY12 EBITDA included the extraordinary income received from a customer terminating a contract. Adjusted for this, EBITDA has grown 29% YoY to INR2.33b, in line with estimate. EBITDA for the LSI business has doubled to INR950m (on a low base). EBITDA from Pharma Business has de-grown by 5 to INR1.75b, impacted by DDSS business. EBITDA Margin Trend Source: Company/MOSL Key highlights of the conference call The management has maintained long-term revenue guidance of 20% CAGR over FY13-15E and has not given any specific guidance for FY14E. The management is confident of achieving this growth on account of (1) higher utilization of new, expanded and existing capacities in Life Science Ingredients and CMO business, and (2) new product launches as well as expansion in new territories in APIs, Generics and Specialty Pharma businesses. During the quarter, the company reported 18.5% revenue growth led by 14% volume growth and favorable currency. The 24% growth in Life Sciences vertical was led by high growth in PPES and Life Sciences Chemical division. Growth in Pharma division was led by the Generic segment. In Life Science Ingredients business, the company continues to face pricing pressure in proprietary products and nutritional ingredients segments. The growth is coming on the back of increase volumes led by commercialization of new capacities. 9 May 2012 2
FDA warning letter: The company has responded to the warning letter in time and FDA has agreed to majority of the remediation measures outlined by the company. However, there management did not share any timeline for the resolution. They had earlier indicated that the warning letter will not have more than USD10m of revenue impact and USD2-3m of EBITDA impact. EBITDA margins are guided to be 21% by FY15E. This will be driven by hedges taken at favorable rates, new launches, change in product mix and higher capacity utilization in Symtet facility. Tax guidance has been increased from earlier 25% to 30% for the next two years. Capex will be to the tune of INR3.5b over the same period. During the quarter, the company reported exceptional item of INR760m: (1) INR650m pertaining to products under development and (2) INR110 of inventory write-off. JOL has net debt of INR34.32b, down INR1.1b QoQ, of which INR0.7b is on account of repayment. The company targets to bring down the D/E ration to <1x over next 3 years. High debt on the books remains concern; Higher interest cost to impact profitability Net debt on JOL's books stands at INR34.32b. It had raised debt in 4QFY11 for the redemption of FCCBs worth USD142m (USD202m incl YTM). The management is targeting to reduce debt by INR4b in FY14. However, we believe this target to be aggressive given the (1) high working capital requirement, (2) large FY13 capex at INR3.5b and (3) Dividend payment to shareholders. The company is also planning to raise USD250m non-convertible debentures to refinance its outstanding debt. The management indicated that this will not increase overall debt levels. Overall interest cost for FY13 has increased by 10% to INR2.3b, despite debt reduction YoY. We believe the increased interest cost will impact profitability. Outlook and Valuation For the FY13-15 period, we expect JOL to record 15.5% topline CAGR, 17% EBITDA CAGR, and 60% EPS CAGR (on a low base). EPS CAGR will be much higher than EBITDA CAGR as company had reported a large forex losses in FY13. High debt (net debt was INR34.32b as of Mar-13) continues to be our main concern area for JOL. We believe JOL needs to restructure its balance sheet significantly for its stock to get re-rated. We also believe that some of its past acquisitions (like Draxis) have been made at expensive valuations, resulting in extended payback periods and lower return ratios. High debt and low RoCE (15-17%) remain overhangs. The stock trades at 5.2x FY14E EPS and 4.6x FY15E EPS. We maintain Neutral with price target of INR213 (6x FY15E EPS). 9 May 2012 3
: an investment profile Company description Jubilant Organosys Limited is the largest specialty chemicals company in India with high degree of vertical integration along with global scale and reach in almost all its key products. Its business model thus spans pharmaceuticals & life sciences, industrial chemicals and performance chemicals. It has forayed into API business (by acquiring Max India's API operations) and into formulations and regulatory services (by acquiring PSI n.v and PSI supply). Key investment arguments A composite and integrated player with offerings across the pharma and specialty chemicals value chain. Continuous forward integration, with global scale capacities in key products and widespread global presence puts Jubilant on the high growth path. Growing share of the profitable Pharma business, driven by CRAMS, steriles & radiopharmaceuticals business, to ensure improved profitability and earnings visibility. Key investment risk High debt on the books is a concern which may impact the profitability going forward - It also lowers RoCE. Adverse foreign currency movement can impact the revenue and profitability of the company. Recent developments Nil Valuation and view For the FY13-15 period, we expect JOL to record 15.4% topline CAGR, 17.2% EBITDA CAGR, and 60% EPS CAGR. EPS CAGR will be much higher than EBITDA CAGR as company had reported a large forex losses in FY13. The stock trades at 5.2x FY14E EPS and 4.6x FY15E EPS. We maintain Neutral with price target of INR213 (6x FY15E EPS). Sector view The CRAMS segment is likely to witness sustained growth over the next few years led by increased out-sourcing from India. Comparative valuations Jubilant Divis Dishman P/E (x) FY14E 5.2 18.5 4.9 FY15E 4.6 14.6 4.1 P/BV (x) FY14E 0.9 4.7 0.5 FY15E 0.8 3.9 0.5 EV/Sales (x) FY14E 0.9 5.0 0.9 FY15E 0.8 4.1 0.7 EV/EBITDA (x) FY14E 4.7 13.5 4.1 FY15E 3.8 10.9 3.3 EPS: MOSL forecast v/s consensus (INR) MOSL Consensus Variation Forecast Forecast (%) FY13 31.0 30.5 1.8 FY14 35.7 37.7-5.3 Target price and recommendation Current Target Upside Reco. Price (INR) Price (INR) (%) 163 213 30.6 Neutral Stock performance (1 year) Shareholding pattern (%) Mar-13 Dec-12 Mar-12 Promoter 49.0 49.0 49.0 Domestic Inst 1.7 2.0 1.5 Foreign 28.3 27.2 28.7 Others 21.0 21.8 20.8 9 May 2012 4
Financials and Valuation 9 May 2012 5
Disclosures This report is for personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement 1. Analyst ownership of the stock No 2. Group/Directors ownership of the stock No 3. Broking relationship with company covered No 4. Investment Banking relationship with company covered No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues. Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. For U.K. This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons. For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: Nihar Oza Kadambari Balachandran Email: niharoza.sg@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com Contact: (+65) 68189232 Contact: (+65) 68189233 / 65249115 Office address: 21 (Suite 31), 16 Collyer Quay, Singapore 049318 Motilal Oswal Securities Ltd Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com